PharmaEssentia Corporation
6446
Rang in aandelen
#1442
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aandeelprijs
$36.89
Marktkapitalisatie
$15.25B
Verandering (1 dag)
-1.28%
Verandering (1 jaar)
144.12%
Land
TW
Handel PharmaEssentia Corporation (6446)
Categorie
Healthcare
P/B-ratio voor PharmaEssentia Corporation (6446)
P/B-ratio op October 2026 TTM: 13.50
Volgens de meest recente financiële rapporten en aandelenkoers van PharmaEssentia Corporation is de huidige P/B-ratio (TTM) 13.50. Eind 2023 had het bedrijf een P/B-ratio van 4.70.
P/B-ratiohistoriek voor PharmaEssentia Corporation van 2010 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 13.50 | 85.23% |
| 2024 | 7.29 | 54.92% |
| 2023 | 4.70 | -57.85% |
| 2022 | 11.16 | -36.95% |
| 2021 | 17.70 | 205.50% |
| 2020 | 5.79 | -44.22% |
| 2019 | 10.39 | -30.22% |
| 2018 | 14.88 | 65.96% |
| 2017 | 8.97 | 16.17% |
| 2016 | 7.72 | -85.09% |
| 2015 | 51.79 | 198.70% |
| 2014 | 17.34 | 0.82% |
| 2013 | 17.20 | -64.44% |
| 2012 | 48.36 | -92.11% |
| 2011 | 613.14 | 490.71% |
| 2010 | 103.80 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -62.67% |
IN
|
